Appendix 11. Numbers and frequencies (%) of responders in ALS IgA in the B cohort and C cohort children Responder frequencies (%; ≥2-fold rises) of ALS IgA responses from baseline to day of peak response -either Day 7 after the first dose or Day 5 after the second dose -against ETVAX antigens in Vaccinees (V) and Placebo (P) recipients given different doses of ETVAX ± dmLT. Statistical differences between responder frequencies in V and P, p<0.0001 for all antigens in both age groups (Fisher's Exact 2-tailed Test; p<0.0005 for all antigens in both groups with adjustments). Fold-rise (geometric mean and range) ALS IgA responses from baseline to day of peak response -either Day 7 after the first dose or Day 5 after the second dose -against ETVAX antigens in Vaccinees (V) and Placebo (P) recipients 12-23 months; statistical differences V vs P, p≤0.04 to p≤ 0.0001 for all antigens in cohorts C1-C3, in cohort C4 only significant for C5 (≤0.004) and LTB (p=0.0005) (2-sample t-test ); with Holm's-Bonferroni adjustment for multiple antigens p≤ 0.04 for all antigens in cohorts C1-C3 and CS5 and LTB in cohort 4. 
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Appendix 16. Plasma IgA and IgG (LTB only) responses in the different B cohorts of children 24-59 months
Fold-rise antibody responses (geometric mean and range) in plasma from baseline to day of peak response -either Day 7 after the first dose or Day 5 after the second dose -against vaccine antigens in 12-23 months old children (IgA responses to all antigens and IgG also to LTB Fold-rise antibody responses (geometric mean and range) in plasma from baseline to day of peak response -either Day 7 after the first dose or Day 5 after the second dose -against vaccine antigens in 6-11 months old children given ETVAX ± dmLT (IgA responses to all antigens and IgG also to LTB groups (Cohorts B, C and D) Comparison of ≥2-fold faecal SIgA responses among 6-11 months old children to ETVAX antigens given placebo or 1/4 adult dose with and without 2.5 µg dmLT on Day 7 (after first dose) and day 28 (14 days after second dose). Statistical differences between vaccine ± dmLT vs. placebo for each vaccine antigen was determined by Fisher's exact test. On Day 7, for CFA/I (a), vaccine + dmLT vs. vaccine alone, p=0.02; for CS3 (b), vaccine + dmLT vs. vaccine alone, p=0.02; for CS6 (c), vaccine + dmLT vs. vaccine alone, p=0.03 and vaccine + dmLT vs. placebo, p=0.046; no significant differences between vaccine alone and vaccine + dmLT was noted day 28. Among evaluable subjects who were non-responders to the first dose, after receipt of a second dose of vaccine or vaccine+dmLT, 4-7 and 3-5 more children responded respectively, depending on vaccine antigen. 
